Research Paper Volume 9, Issue 12 pp 2695—2716

A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas

Figure 1. Relapse free survival (left panel) and overall survival (right panel) rates in groups of patients as a function of CDK6 expression. Two groups of patients with CDK6 expression higher (grey curves) or lower (black curves) than cutoff values (bottom left in the graphs) have been defined for each trait. The number of patients in each group is indicated in parentheses. Cutoffs are expression values that maximized the significance of log-rank tests. p values of log-rank tests are at the bottom right in each box. Cutoff value is a gene-level transcription estimate, in RNA-Seq by Expectation Maximization (RSEM) normalized counts (downloaded from TCGA portal).